Scarica l'app Stockscreener
103.58
5.93%
5.80
Dopo l'orario di chiusura:
103.58
Precedente Chiudi:
$97.78
Aprire:
$99.43
Volume 24 ore:
1.66M
Relative Volume:
1.32
Capitalizzazione di mercato:
$7.28B
Reddito:
$3.99B
Utile/perdita netta:
$463.16M
Rapporto P/E:
14.59
EPS:
7.1
Flusso di cassa netto:
$1.10B
1 W Prestazione:
-12.36%
1M Prestazione:
+3.06%
6M Prestazione:
-18.91%
1 anno Prestazione:
-5.52%
Intervallo 1D:
$99.13
$105.28
Intervallo di 1 settimana:
$97.50
$118.00
Portata 52W:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
103.58 | 7.28B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz outlines $4.15B-$4.4B revenue target for 2025 amid growth in neuroscience portfolio and new oncology approvals - MSN
Avadel Pharma gains after appeals court ruling in Lumryz case with Jazz Pharma - MSN
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update - Yahoo Finance
Hikma $50M Deal to Settle Xyrem Antitrust Claims - USA Herald
Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts - simplywall.st
Jazz Pharmaceuticals plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2025 Earnings Call Transcript - Insider Monkey
Jazz Pharma stock falls after lowered full year guidance - MSN
Hikma Cuts $50M Deal To End Antitrust Claims In Xyrem MDL - Law360
Hikma Pharma to pay $50 million to settle narcolepsy drug antitrust case - Reuters
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook - MSN
After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM) - The Globe and Mail
Decoding Jazz Pharmaceuticals PLC (JAZZ): A Strategic SWOT Insig - GuruFocus
Jazz Pharmaceuticals (JAZZ) Rating Maintained Despite Price Target Cut | JAZZ Stock News - GuruFocus
RBC Capital Maintains Outperform Rating on Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ): Morgan Stanley Adjusts Price Target - GuruFocus
Jazz Pharmaceuticals (JAZZ) Target Price Lowered by Piper Sandler | JAZZ Stock News - GuruFocus
RBC Capital Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Maintains Strong Momentum with 'Buy' Rating | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ): Among Billionaire Ray Dalio’s Bridgewater’s Stock Picks with Huge Upside Potential - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Sees Price Target Cut Amid Revenue Miss | JAZZ Stock News - GuruFocus
Morgan Stanley Cuts Price Target on Jazz Pharmaceuticals to $166 From $183, Keeps Overweight Rating - marketscreener.com
Analyst Adjusts Price Target for Jazz Pharmaceuticals (JAZZ) | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView
Jazz Pharmaceuticals (JAZZ) Price Target Upgraded by BofA Analyst | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals (JAZZ) Price Target Reduced by Morgan Stanley | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals PLC (JAZZ) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Jazz Pharmaceuticals PLC (JAZZ) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Jazz Pharmaceuticals PLC (JAZZ) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Legal Challenges - GuruFocus
Jazz Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Jazz: Q1 Earnings Snapshot - The Washington Post
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings - Yahoo Finance
Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals Q1 2025 Earnings: EPS Beats Estimates at $1 - GuruFocus
Jazz Pharmaceuticals misses estimates, slashes guidance on litigation costs - Investing.com Australia
Jazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets - Yahoo Finance
Jazz Pharma stock falls after lowered full year guidance (JAZZ:NASDAQ) - Seeking Alpha
Jazz Pharmaceuticals (JAZZ) Updates 2025 Financial Guidance After Key Developments | JAZZ Stock News - GuruFocus
Avadel Pharmaceuticals (AVDL) Rises After Court Victory - GuruFocus
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Jazz Q1 Earnings, Revenue Decline; Updates Outlook - marketscreener.com
Jazz Pharmaceuticals PLC reports results for the quarter ended March 31Earnings Summary - TradingView
Jazz Pharmaceuticals (JAZZ) Reports Q1 Revenue Below Expectations | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Q1 2025 Earnings: EPS Beats Estimates at $1.68, Revenue Misses at $898 Million - GuruFocus
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance | JAZZ Stock News - GuruFocus
Northpointe Bancshares Schedules Q1 2025 Earnings Call: Key Details for Investors - Stock Titan
Federal Circuit Reverses Block on Avadel’s Sleep Drug Trials - Bloomberg Law News
Avadel Pharma seesaw after appeals court ruling in Lumryz case with Jazz Pharma (update) (AVDL:NASDAQ) - Seeking Alpha
Billionaire Ray Dalio’s Bridgewater’s 10 Stock Picks with Huge Upside Potential - Insider Monkey
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):